# Nancy P Mendenhall

List of Publications by Year
in descending order



| 208 | 6,230 | 53939 47 | 100535 70 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 210 | 210 | 210 | 5839 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Insurance Approval for Definitive Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2022, 8, 36-42. | 0.9 | 3 |
| 2 | Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 21-27. | 0.9 | 0 |
| 3 | Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2022, 112, 158-166. | 0.4 | 7 |
| 4 | Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 76-81. | 0.9 | 0 |
| 5 | Hyperfractionated-Accelerated Reirradiation with Proton Therapy for Radiation-Associated Breast Angiosarcoma. International Journal of Particle Therapy, 2022, 8, 55-67. | 0.9 | 2 |
| 6 | RBEâ€weighted dose and its impact on the risk of acute coronary event for breast cancer patients treated with intensity modulated proton therapy. Journal of Applied Clinical Medical Physics, 2022, 23, . | 0.8 | 3 |
| 7 | Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. International Journal of Radiation Oncology Biology Physics, 2022, 113, 542-551. | 0.4 | 7 |
| 8 | Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer. Acta OncolÃ³gica, 2022, 61, 468-477. | 0.8 | 1 |
| 9 | Incorporation of the LETd-weighted biological dose in the evaluation of breast intensity-modulated proton therapy plans. Acta OncolÃ³gica, 2021, 60, 252-259. | 0.8 | 9 |
| 10 | Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 109, 220-230. | 0.4 | 7 |
| 11 | A comparative study of prostate PTV margins for patients using hydrogel spacer or rectal balloon in proton therapy. Physica Medica, 2021, 81, 47-51. | 0.4 | 6 |
| 12 | Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy. International Journal of Particle Therapy, 2021, 7, 52-64. | 0.9 | 0 |
| 13 | Consensus Statement on Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2021, 8, 1-16. | 0.9 | 9 |
| 14 | A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1082-1089. | 0.4 | 19 |
| 15 | What men want: Results from a national survey on decision making for prostate cancer treatment and research participation. Clinical and Translational Science, 2021, 14, 2314-2326. | 1.5 | 4 |
| 16 | Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1â€“4N1â€“3M0 Breast Cancer. Annals of Surgical Oncology, 2021, 28, 5775-5787. | 0.7 | 8 |
| 17 | ASO Visual Abstract: A 5-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1â€“4N1â€“3M0ÂBreast Cancer. Annals of Surgical Oncology, 2021, , 1. | 0.7 | 0 |
| 18 | Normal tissue complication probability models for prospectively scored late rectal and urinary morbidity after proton therapy of prostate cancer. Physics and Imaging in Radiation Oncology, 2021, 20, 62-68. | 1.2 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. Value in Health, 2021, 25, 171-177. | 0.1 | 0 |
| 20 | The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154. | 1.1 | 51 |
| 21 | Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy. Radiotherapy and Oncology, 2020, 142, 253-260. | 0.3 | 17 |
| 22 | Using Robust Optimization for Skin Flashing in Intensity Modulated Radiation Therapy for Breast Cancer Treatment: A Feasibility Study. Practical Radiation Oncology, 2020, 10, 59-69. | 1.1 | 9 |
| 23 | Patient-specific quality assurance and plan dose errors on breast intensity-modulated proton therapy. Physica Medica, 2020, 77, 84-91. | 0.4 | 2 |
| 24 | Radiotherapy in Early-stage Gastric MALT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 770-775. | 0.6 | 4 |
| 25 | Multivariate normal tissue complication probability models for rectal and bladder morbidity in prostate cancer patients treated with proton therapy. Radiotherapy and Oncology, 2020, 153, 279-288. | 0.3 | 6 |
| 26 | Concomitant Radiation Recall Dermatitis and Organizing Pneumonia following Breast Radiotherapy: A Case Report. Case Reports in Oncology, 2020, 13, 875-882. | 0.3 | 1 |
| 27 | Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 522-529. | 0.4 | 2 |
| 28 | Dosimetric consequences of image guidance techniques on robust optimized intensity-modulated proton therapy for treatment of breast Cancer. Radiation Oncology, 2020, 15, 47. | 1.2 | 8 |
| 29 | Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2020, 6, 11-16. | 0.9 | 4 |
| 30 | Comparison of Techniques for Involved-Site Radiation Therapy in Patients With Lower Mediastinal Lymphoma. Practical Radiation Oncology, 2019, 9, 426-434. | 1.1 | 22 |
| 31 | Tomayto, tomahto: prescription dose and mean heart dose in evaluating the cardiac impact of involved-field radiation therapy for Hodgkin lymphoma survivors. Acta OncolÃ³gica, 2019, 58, 1783-1785. | 0.8 | 2 |
| 32 | Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors. Advances in Radiation Oncology, 2019, 4, 699-705. | 0.6 | 9 |
| 33 | A comprehensive dosimetric study of Monte Carlo and pencilâ€beam algorithms on intensityâ€modulated proton therapy for breast cancer. Journal of Applied Clinical Medical Physics, 2019, 20, 128-136. | 0.8 | 24 |
| 34 | Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: I would treat prostate cancer with proton therapy. Journal of Applied Clinical Medical Physics, 2019, 20, 7-14. | 0.8 | 1 |
| 35 | The impact of dose algorithms on tumor control probability in intensity-modulated proton therapy for breast cancer. Physica Medica, 2019, 61, 52-57. | 0.4 | 5 |
| 36 | Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer. Advances in Radiation Oncology, 2019, 4, 500-506. | 0.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. Cancer Investigation, 2019, 37, 85-89. | 0.6 | 5 |
| 38 | Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. Radiotherapy and Oncology, 2019, 134, 204-210. | 0.3 | 5 |
| 39 | In Regard to Stecklein etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1280-1281. | 0.4 | 2 |
| 40 | ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer. Practical Radiation Oncology, 2019, 9, 38-48. | 1.1 | 16 |
| 41 | Pulmonary Function after Proton Therapy for Hodgkin Lymphoma. International Journal of Particle Therapy, 2019, 5, 1-4. | 0.9 | 1 |
| 42 | Cardiac MRI for Detecting Early Cardiac Toxicity after Proton Therapy for Hodgkin Lymphoma. International Journal of Particle Therapy, 2019, 5, 41-44. | 0.9 | 5 |
| 43 | Insurance Coverage for Adjuvant Proton Therapy in the Definitive Treatment of Breast Cancer. International Journal of Particle Therapy, 2019, 6, 26-30. | 0.9 | 6 |
| 44 | Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. Acta OncolÃ³gica, 2018, 57, 582-588. | 0.8 | 17 |
| 45 | Outcomes following proton therapy for pediatric ependymoma. Acta OncolÃ³gica, 2018, 57, 644-648. | 0.8 | 51 |
| 46 | Radiotherapy in the Management of Orbital Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 100-106. | 0.6 | 14 |
| 47 | Late Effects After Radiotherapy for Childhood Low-grade Glioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 307-312. | 0.6 | 31 |
| 48 | Novel Radiotherapy Techniques for Breast Cancer. Annual Review of Medicine, 2018, 69, 277-288. | 5.0 | 50 |
| 49 | Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker Placement. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1243-1245. | 0.6 | 1 |
| 50 | Radiotherapy for Orbital Pseudotumor: The University of Florida Experience. Cancer Investigation, 2018, 36, 330-337. | 0.6 | 7 |
| 51 | Radiotherapy for extranodal classic Hodgkin lymphoma of the maxillary sinus: Case report and literature review. Head and Neck, 2018, 40, E96-E99. | 0.9 | 1 |
| 52 | Prognostic factors of radiation dermatitis following passive-scattering proton therapy for breast cancer. Radiation Oncology, 2018, 13, 72. | 1.2 | 35 |
| 53 | Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 494-497. | 0.4 | 14 |
| 54 | Conventional Radiation Therapy Compared With Stereotactic Conformal Therapyâ€"A Rare and Laudable Randomized Trial. JAMA Oncology, 2017, 3, 1376. | 3.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. Advances in Radiation Oncology, 2017, 2, 197-203. | 0.6 | 11 |
| 56 | Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842. | 0.4 | 66 |
| 57 | Biological dose and complication probabilities for the rectum and bladder based on linear energy transfer distributions in spot scanning proton therapy of prostate cancer. Acta OncolÃ³gica, 2017, 56, 1413-1419. | 0.8 | 19 |
| 58 | Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta OncolÃ³gica, 2017, 56, 963-970. | 0.8 | 31 |
| 59 | Sperm preservation and neutron contamination following proton therapy for prostate cancer study. Acta OncolÃ³gica, 2017, 56, 17-20. | 0.8 | 6 |
| 60 | Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. World Journal of Gastrointestinal Surgery, 2017, 9, 103. | 0.8 | 13 |
| 61 | A Technical Guide for Passive Scattering Proton Radiation Therapy for Breast Cancer. International Journal of Particle Therapy, 2017, 3, 473-484. | 0.9 | 10 |
| 62 | Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy. International Journal of Particle Therapy, 2017, 3, 461-472. | 0.9 | 2 |
| 63 | Comparing Breath Hold and Free Breathing during Intensity-Modulated Radiation Therapy and Proton Therapy in Patients with Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2017, 3, 492-496. | 0.9 | 15 |
| 64 | Evaluating Cardiac Biomarkers after Chemotherapy and Proton Therapy for Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2017, 4, 35-38. | 0.9 | 4 |
| 65 | Proton Therapy for Pediatric Hodgkin Lymphoma. Pediatric Blood and Cancer, 2016, 63, 1522-1526. | 0.8 | 20 |
| 66 | Initial Report of a Prospective Dosimetric and Clinical Feasibility Trial Demonstrates the Potential of Protons to Increase the Therapeutic Ratio in Breast Cancer Compared With Photons. International Journal of Radiation Oncology Biology Physics, 2016, 95, 411-421. | 0.4 | 93 |
| 67 | Reducing Anesthesia and Health Care Cost Through Utilization of Child Life Specialists in Pediatric Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 96, 401-405. | 0.4 | 51 |
| 68 | ACR AppropriatenessÂ® Hodgkin Lymphomaâ€"Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 384-395. | 0.6 | 3 |
| 69 | ACR AppropriatenessÂ® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 535-544. | 0.6 | 4 |
| 70 | Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 261-265. | 0.6 | 7 |
| 71 | Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 422-434. | 0.4 | 90 |
| 72 | Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound. International Journal of Radiation Oncology Biology Physics, 2016, 95, 465-471. | 0.4 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Patient-Reported Quality of Life in Men with Transurethral Resection of the Prostate Undergoing Proton Therapy for Management of Prostate Cancer. International Journal of Particle Therapy, 2016, 2, 518-524. | 0.9 | 4 |
| 74 | Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer. International Journal of Particle Therapy, 2016, 3, 21-26. | 0.9 | 4 |
| 75 | Mesenchymal Chondrosarcoma. International Journal of Particle Therapy, 2016, 3, 300-304. | 0.9 | 14 |
| 76 | Controversies in proton therapy for prostate cancer. Chinese Clinical Oncology, 2016, 5, 55-55. | 0.4 | 3 |
| 77 | ACR Appropriateness CriteriaÂ® Recurrent Hodgkin Lymphoma. Oncology, 2016, 30, 1099-103, 1106-8. | 0.4 | 2 |
| 78 | Hemorrhagic Radiation Cystitis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 331-336. | 0.6 | 41 |
| 79 | ACR Appropriateness CriteriaÂ® Diffuse Large B-Cell Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 610-620. | 0.6 | 9 |
| 80 | Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2019-2024. | 0.6 | 13 |
| 81 | Rectal Toxicity After Proton Therapy For Prostate Cancer: An Analysis of Outcomes of Prospective Studies Conducted at the University of Florida Proton Therapy Institute. International Journal of Radiation Oncology Biology Physics, 2015, 91, 172-181. | 0.4 | 41 |
| 82 | A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Acta OncolÃ³gica, 2015, 54, 825-831. | 0.8 | 15 |
| 83 | Proton therapy in the management of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2608-2612. | 0.6 | 19 |
| 84 | Fiducial Markers, Saline, and Balloons to Locate and Stabilize the Prostate during Proton Therapy. International Journal of Particle Therapy, 2015, 2, 29-36. | 0.9 | 2 |
| 85 | Local control in non-metastatic medulloblastoma. Acta OncolÃ³gica, 2014, 53, 1151-1157. | 0.8 | 6 |
| 86 | Angiosarcoma after breast-conserving therapy: Long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta OncolÃ³gica, 2014, 53, 235-241. | 0.8 | 31 |
| 87 | Proton Therapy for Skull Base Chordomas: An Outcome Study from the University of Florida Proton Therapy Institute. Journal of Neurological Surgery, Part B: Skull Base, 2014, 75, 053-057. | 0.4 | 43 |
| 88 | Comparative effectiveness study of patientâ€reported outcomes after proton therapy or intensityâ€modulated radiotherapy for prostate cancer. Cancer, 2014, 120, 1076-1082. | 2.0 | 82 |
| 89 | Late toxicity following craniospinal radiation for early-stage medulloblastoma. Acta OncolÃ³gica, 2014, 53, 471-480. | 0.8 | 58 |
| 90 | Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy. Acta OncolÃ³gica, 2014, 53, 1298-1304. | 0.8 | 180 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Salvage of Locally Recurrent Prostate Cancer After Definitive Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 411-416. | 0.6 | 9 |
| 92 | Submandibular Gland-sparing Intensity-modulated Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 514-516. | 0.6 | 26 |
| 93 | Can Proton Therapy Improve the Therapeutic Ratio in Breast Cancer Patients at Risk for Nodal Disease?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 568-574. | 0.6 | 31 |
| 94 | Management of Radiation Proctitis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 517-523. | 0.6 | 18 |
| 95 | ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. Journal of the American College of Radiology, 2014, 11, 1026-1033.e3. | 0.9 | 16 |
| 96 | Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 596-602. | 0.4 | 103 |
| 97 | Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1053-1059. | 0.4 | 60 |
| 98 | Testosterone Replacement Therapy in Men with Prostate Cancer after Proton Therapy. International Journal of Particle Therapy, 2014, 1, 682-691. | 0.9 | 1 |
| 99 | Bacterial Urinary Tract Infection after Fiducial Marker Placement or Prostate Biopsy. International Journal of Particle Therapy, 2014, 1, 745-758. | 0.9 | 2 |
| 100 | Patient-reported Hip Symptoms following Treatment with Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2014, 1, 14-21. | 0.9 | 2 |
| 101 | Advancing the Therapeutic Index in Stage III/IV Pediatric Hodgkin Lymphoma with Proton Therapy. International Journal of Particle Therapy, 2014, 1, 343-356. | 0.9 | 6 |
| 102 | Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 3-8. | 0.6 | 56 |
| 103 | A treatment planning comparison of highly conformal radiation therapy for pediatric low-grade brainstem gliomas. Acta OncolÃ³gica, 2013, 52, 594-599. | 0.8 | 13 |
| 104 | Radiotherapeutic Management of Lymphomas. , 2013, , 1015-1025. | | 0 |
| 105 | Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. Acta OncolÃ³gica, 2013, 52, 463-469. | 0.8 | 17 |
| 106 | Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta OncolÃ³gica, 2013, 52, 498-505. | 0.8 | 66 |
| 107 | Outcomes in men with large prostates (â‰¥ 60 cm<sup>3</sup>) treated with definitive proton therapy for prostate cancer. Acta OncolÃ³gica, 2013, 52, 470-476. | 0.8 | 10 |
| 108 | Proton therapy in a pediatric patient with stage III Hodgkin lymphoma. Acta OncolÃ³gica, 2013, 52, 592-594. | 0.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. Acta OncolÃ³gica, 2013, 52, 492-497. | 0.8 | 13 |
| 110 | Hip fractures and pain following proton therapy for management of prostate cancer. Acta OncolÃ³gica, 2013, 52, 486-491. | 0.8 | 10 |
| 111 | When is Elective Pelvic Lymph Node Irradiation Indicated in Definitive Radiotherapy for Localized Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 644-647. | 0.6 | 4 |
| 112 | Improving the Therapeutic Ratio by Using Proton Therapy in Patients With Stage I or II Seminoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 31-37. | 0.6 | 18 |
| 113 | Androgen Deprivation Therapy and Definitive Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 530-534. | 0.6 | 8 |
| 114 | Radiation Therapy for Angiosarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 174-180. | 0.6 | 41 |
| 115 | Protonâ€based chemoradiation for synchronous bilateral nonâ€smallâ€cell lung cancers: A case report. Thoracic Cancer, 2013, 4, 198-202. | 0.8 | 8 |
| 116 | Radiotherapy for Cutaneous Angiosarcoma. , 2013, , 189-195. | | 1 |
| 117 | Radiation Therapy of Cutaneous Lymphoma. , 2013, , 205-213. | | 0 |
| 118 | Reduction of prostate intrafraction motion using gasâ€release rectal balloons. Medical Physics, 2012, 39, 5869-5873. | 1.6 | 9 |
| 119 | Radiation Therapy Modalities for Prostate Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 450. | 3.8 | 8 |
| 120 | Proton Therapy of Cancers of the Nasal Cavity and Paranasal Sinusesâ€"the UFPTI Experience. Journal of Neurological Surgery, Part B: Skull Base, 2012, 73, . | 0.4 | 0 |
| 121 | Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 213-221. | 0.4 | 95 |
| 122 | Outcomes of Patients With Non-Hodgkin's Lymphoma Treated With Bexxar With or Without External-Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1122-1127. | 0.4 | 8 |
| 123 | Proton Radiotherapy for Prostate Cancer Is Not Associated With Post-Treatment Testosterone Suppression. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1222-1226. | 0.4 | 20 |
| 124 | Protons Offer Reduced Normal-Tissue Exposure for Patients Receiving Postoperative Radiotherapy for Resected Pancreatic Head Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 158-163. | 0.4 | 49 |
| 125 | Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study. International Journal of Radiation Oncology Biology Physics, 2012, 83, 260-267. | 0.4 | 72 |
| 126 | Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 449-455. | 0.4 | 126 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Urethral Catheterization Facilitates Preradiation Fiducial Marker Placement in Postprostatectomy Patients. Journal of Endourology, 2012, 26, 467-468. | 1.1 | 1 |
| 128 | Cutaneous Merkel cell carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2012, 33, 88-92. | 0.6 | 13 |
| 129 | Responseâ€dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 1259-1265. | 0.8 | 74 |
| 130 | Proton Therapy With Concurrent Chemotherapy for Nonâ€“Small-Cell Lung Cancer: Technique and Early Results. Clinical Lung Cancer, 2012, 13, 352-358. | 1.1 | 34 |
| 131 | Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer, 2012, 118, 4619-4626. | 2.0 | 51 |
| 132 | Proton therapy for lung cancer. Thoracic Cancer, 2012, 3, 109-116. | 0.8 | 10 |
| 133 | Selective nodal irradiation of regionally advanced nonâ€smallâ€cell lung cancer with proton therapy and IMRT: A dosimetric comparison. Thoracic Cancer, 2012, 3, 169-174. | 0.8 | 4 |
| 134 | Proton therapy for head and neck cancer: Rationale, potential indications, practical considerations, and current clinical evidence. Acta OncolÃ³gica, 2011, 50, 763-771. | 0.8 | 59 |
| 135 | Head and neck osteosarcoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2011, 32, 597-600. | 0.6 | 68 |
| 136 | Proton Radiation Therapy Offers Reduced Normal Lung and Bone Marrow Exposure for Patients Receiving Dose-Escalated Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer: A Dosimetric Study. Clinical Lung Cancer, 2011, 12, 252-257. | 1.1 | 75 |
| 137 | Consolidative Proton Therapy Following High-dose Chemotherapy and Autologous Stem Cell Transplant in an Adolescent with Relapsed Hodgkin Lymphoma. Journal of Adolescent and Young Adult Oncology, 2011, 1, 103-106. | 0.7 | 3 |
| 138 | Proton Therapy of Esthesioneuroblastoma: The UFPTI Experience. Skull Base, 2011, 21, . | 0.4 | 0 |
| 139 | Is Radical Prostatectomy the â€œGold Standardâ€•for Localized Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 511-515. | 0.6 | 23 |
| 140 | Angiosarcoma after breastâ€conserving therapy. Cancer, 2010, 116, 1872-1878. | 2.0 | 69 |
| 141 | In Response to â€œIn Regards to Chera BS et alâ€• International Journal of Radiation Oncology Biology Physics, 2010, 78, 316. | 0.4 | 0 |
| 142 | Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric comparison with photon-based stereotactic body radiotherapy. Radiotherapy and Oncology, 2010, 97, 425-430. | 0.3 | 63 |
| 143 | Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 1559-1562. | 0.6 | 19 |
| 144 | Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope, 2009, 119, 899-906. | 1.1 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope, 2009, 119, 1994-1999. | 1.1 | 144 |
| 146 | The Dynamic Tumor Bed: Volumetric Changes in the Lumpectomy Cavity During Breast-Conserving Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 695-701. | 0.4 | 52 |
| 147 | Dosimetric Comparison of Three Different Involved Nodal Irradiation Techniques for Stage II Hodgkin's Lymphoma Patients: Conventional Radiotherapy, Intensity-Modulated Radiotherapy, and Three-Dimensional Proton Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1173-1180. | 0.4 | 113 |
| 148 | The Management of Adult Soft Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 436-442. | 0.6 | 90 |
| 149 | Erectile Dysfunction After Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 443-447. | 0.6 | 25 |
| 150 | Long-term Outcomes for Stage Iâ€“II Aggressive Non-Hodgkin Lymphoma of Waldeyer's Ring. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 233-237. | 0.6 | 13 |
| 151 | Differences Between Current and Historical Breast Cancer Axillary Lymph Node Irradiation Based on Arm Position. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 381-386. | 0.6 | 7 |
| 152 | Xerostomia in Long-term Survivors of Aggressive Non-Hodgkin's Lymphoma of Waldeyer's Ring. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 145-149. | 0.6 | 12 |
| 153 | Accuracy of Breast Cancer Axillary Lymph Node Treatment Plans Based on 2-Dimensional Imaging. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 387-395. | 0.6 | 2 |
| 154 | Postprostatectomy Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 529-534. | 0.6 | 5 |
| 155 | Proton Therapy for Maxillary Sinus Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 296-303. | 0.6 | 39 |
| 156 | Does Surgical Closure Technique Affect Early Mammographic Detection of Tumor Recurrence After Breast-Conserving Therapy?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 499-503. | 0.6 | 1 |
| 157 | Locoregional Recurrence after Mastectomy. , 2009, , 1181-1187. | | 0 |
| 158 | Proton Therapy of Paranasal Sinus Tumors: An Update of the UFPTI Experience. Skull Base, 2009, 19, . | 0.4 | 0 |
| 159 | Adjuvant radiotherapy for cutaneous melanoma. Cancer, 2008, 112, 1189-1196. | 2.0 | 33 |
| 160 | Doseâ€“Volume Differences for Computed Tomography and Magnetic Resonance Imaging Segmentation and Planning for Proton Prostate Cancer Therapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1426-1433. | 0.4 | 4 |
| 161 | Subsequent Malignancies in Children Treated for Hodgkin's Disease: Associations With Gender and Radiation Dose. International Journal of Radiation Oncology Biology Physics, 2008, 72, 24-33. | 0.4 | 116 |
| 162 | Unilateral and Bilateral Breast Cancer in Women Surviving Pediatric Hodgkin's Disease. International Journal of Radiation Oncology Biology Physics, 2008, 72, 34-40. | 0.4 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Is There a Role for Routine Use of MRI in Selection of Patients for Breast-Conserving Cancer Therapy?. Journal of the American College of Surgeons, 2008, 206, 1045-1050. | 0.2 | 55 |
| 164 | ACR Appropriateness CriteriaÂ® on Hodgkin's Lymphomaâ€"Favorable Prognosis Stage I and II. Journal of the American College of Radiology, 2008, 5, 1054-1066. | 0.9 | 3 |
| 165 | Definitive Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 496-503. | 0.6 | 24 |
| 166 | Salivary Gland Pleomorphic Adenoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 95-99. | 0.6 | 108 |
| 167 | Re-irradiation of Head and Neck Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 393-398. | 0.6 | 46 |
| 168 | Proton Therapy of Paranasal Sinus Tumors: The UFPTI Experience. Skull Base, 2008, 18, . | 0.4 | 0 |
| 169 | Clinical Presentation and Outcomes of Lymphocyte-predominant Hodgkin Disease at the University of Florida. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 601-606. | 0.6 | 21 |
| 170 | Is the Berg Axillary Lymph Node Categorization Useful in the 3D Environment?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 69-77. | 0.6 | 5 |
| 171 | Ameloblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 645-648. | 0.6 | 143 |
| 172 | Skin Cancer of the Head and Neck With Perineural Invasion. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 93-96. | 0.6 | 126 |
| 173 | Inverted Papilloma of the Nasal Cavity and Paranasal Sinuses. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 560-563. | 0.6 | 54 |
| 174 | Giant Cell Tumor of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 96-99. | 0.6 | 205 |
| 175 | Pigmented Villonodular Synovitis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 548-550. | 0.6 | 70 |
| 176 | Cutaneous Angiosarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 524-528. | 0.6 | 165 |
| 177 | A Phase II Study of Gemcitabine in Patients With Relapsed or Refractory Low-Grade Non-Hodgkin Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 165-168. | 0.6 | 9 |
| 178 | Minimizing Local Recurrence after Breast Conserving Therapy Using Intraoperative Shaved Margins to Determine Pathologic Tumor Clearance. Journal of the American College of Surgeons, 2005, 201, 855-861. | 0.2 | 79 |
| 179 | Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck. Cancer, 2005, 104, 332-337. | 2.0 | 29 |
| 180 | The Impact of Central Quality Assurance Review Prior to Radiation Therapy on Protocol Compliance: POG 9426, a Trial in Pediatric Hodgkinâ€™s Disease.. Blood, 2005, 106, 753-753. | 0.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Consensus statement on postmastectomy radiation therapy. International Journal of Radiation Oncology Biology Physics, 1999, 44, 989-990. | 0.4 | 275 |
| 182 | Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. , 1999, 86, 2138-2142. | | 108 |
| 183 | Carcinoma of the skin metastatic to the parotid area lymph nodes. , 1998, 20, 369-373. | | 61 |
| 184 | Medulloblastoma: timeâ€“dose relationship based on a 30-year review. International Journal of Radiation Oncology Biology Physics, 1998, 42, 147-154. | 0.4 | 73 |
| 185 | Carcinoma of the skin metastatic to the parotid area lymph nodes. Head and Neck, 1998, 20, 369-373. | 0.9 | 2 |
| 186 | Lymphocyte predominant Hodgkin Disease: Clinico-pathologic features and results of treatmentâ€”The pediatric oncology group experience. , 1997, 29, 519-525. | | 44 |
| 187 | Manpower needs for radiation oncology: A preliminary report of the ASTRO Human Resources Committee. International Journal of Radiation Oncology Biology Physics, 1996, 35, 809-820. | 0.4 | 34 |
| 188 | Value of Thallium-201 SPECT Imaging in Childhood Brain Tumors. Pediatric Neurosurgery, 1994, 20, 11-18. | 0.4 | 25 |
| 189 | High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Medical and Pediatric Oncology, 1994, 23, 428-436. | 1.0 | 58 |
| 190 | XNEO: Decision support system for efficient management of medulloblastoma. Pediatric Neurology, 1994, 11, 102-103. | 1.0 | 0 |
| 191 | Topical Review Article: Brainstem Glioma: I. Pathology, Clinical Features, and Therapy. Journal of Child Neurology, 1993, 8, 112-128. | 0.7 | 77 |
| 192 | Local control and function after twice-a-day radiotherapy for Ewing's Sarcoma of bone. International Journal of Radiation Oncology Biology Physics, 1991, 21, 1509-1515. | 0.4 | 55 |
| 193 | Local control and function after twice-a-day radiation therapy for Ewing's sarcoma. International Journal of Radiation Oncology Biology Physics, 1990, 19, 124. | 0.4 | 0 |
| 194 | The impact of pelvic recurrence and elective pelvic irradiation on survival and treatment morbidity in early-stage Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1990, 19, 163-164. | 0.4 | 0 |
| 195 | Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function. International Journal of Radiation Oncology Biology Physics, 1989, 16, 79-84. | 0.4 | 75 |
| 196 | The impact of stage and treatment modality on the likelihood of second malignancies and hematopoietic disorders in Hodgkin's disease. Radiotherapy and Oncology, 1989, 14, 219-229. | 0.3 | 22 |
| 197 | High-risk ewing's sarcoma: end-intensification using autologous bone marrow transplantation. International Journal of Radiation Oncology Biology Physics, 1988, 15, 53-59. | 0.4 | 52 |
| 198 | Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiotherapy and Oncology, 1988, 12, 177-185. | 0.3 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Postoperative Radiation and Implant Capsule Contraction. Annals of Plastic Surgery, 1988, 20, 35-38. | 0.5 | 12 |
| 200 | The management of primary lymphoma of bone. Radiotherapy and Oncology, 1987, 9, 137-145. | 0.3 | 61 |
| 201 | T2â€“T4 Carcinoma of the skin of the head and neck treated with radical irradiation. International Journal of Radiation Oncology Biology Physics, 1987, 13, 975-981. | 0.4 | 46 |
| 202 | High-risk Ewing's sarcoma: End intensification using bone marrow transplantation. International Journal of Radiation Oncology Biology Physics, 1987, 13, 181-182. | 0.4 | 4 |
| 203 | CARCINOMA OF THE NASAL VESTIBULE TREATED WITH RADIATION THERAPY. Laryngoscope, 1987, 97, 626???632. | 1.1 | 23 |
| 204 | The acute and late effects of mantle irradiation for hodgkins disease on pulmonary function. International Journal of Radiation Oncology Biology Physics, 1986, 12, 110-111. | 0.4 | 3 |
| 205 | 16. Diffuse Lymphoma of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 1985, 8, 16. | 0.6 | 1 |
| 206 | 14. Management of Advanced Non-HodgkinÊ¼s Lymphomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1985, 8, 16. | 0.6 | 1 |
| 207 | Parotid area lymph node metastases from carcinoma of the skin. International Journal of Radiation Oncology Biology Physics, 1985, 11, 707-714. | 0.4 | 48 |
| 208 | Carcinoma of the nasal vestibule. International Journal of Radiation Oncology Biology Physics, 1984, 10, 627-637. | 0.4 | 35 |